Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIndivior Regulatory News (INDV)

Share Price Information for Indivior (INDV)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,296.00
Bid: 1,300.00
Ask: 1,306.00
Change: -19.00 (-1.44%)
Spread: 6.00 (0.462%)
Open: 1,325.00
High: 1,325.00
Low: 1,284.00
Prev. Close: 1,315.00
INDV Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Court Approval Concludes Antitrust MDL

29 Feb 2024 07:00

RNS Number : 8632E
Indivior PLC
29 February 2024
 

Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation

 

Richmond, VA, February 29, 2024 - Indivior PLC (LSE: INDV; Nasdaq: INDV), a leading addiction treatment company, today announced that its subsidiary, Indivior Inc., has received final Court approval for its settlement with the Direct Purchaser class, concluding the anti-trust multi-district litigation ("MDL") matter.

 

On October 22, 2023, Indivior Inc. entered into a settlement agreement with the remaining Direct Purchaser class for $385m. On February 27, 2024, the United States District Court for the Eastern District of Pennsylvania entered an order granting final judgement and order of dismissal approving the Direct Purchaser class settlement and dismissing the Direct Purchaser class claims. This ruling concludes the Antitrust MDL.

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat addiction and serious mental illnesses. Our vision is that all patients around the world will have access to evidence-based treatment for the chronic conditions and co-occurring disorders of substance use disorder (SUD). Indivior is dedicated to transforming SUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to both expand on its heritage in this category and potentially address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder. Headquartered in?the United States?in?Richmond, VA, Indivior employs more than 1,100 individuals globally and its portfolio of products is available in 37 countries worldwide. Visit?www.indivior.com?to learn more. Connect with Indivior on LinkedIn by visiting?www.linkedin.com/company/indivior.

 

Media Contacts:

US Media:

Cassie France-Kelly

Vice President, Communications

Indivior PLC

Tel: 804-724-0327

 

UK Media:

Teneo

Tel: +44 207-353-4200

 

Investors and Analysts

Jason Thompson

Vice President, Investor Relations

Indivior PLC

Tel: 804-402-7123

 

Tim Owens

Director, Investor Relations

Indivior PLC

Tel: 804-263-3978

 

 

-ends-

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBIGDDBXDDGSI
Date   Source Headline
18th Aug 20204:09 pmRNSHolding(s) in Company
10th Aug 20209:15 amRNSHolding(s) in Company
5th Aug 20208:00 amRNSHolding(s) in Company
3rd Aug 20207:18 amRNSTotal Voting Rights
30th Jul 20207:12 amRNSHalf-year Report
27th Jul 20204:00 pmRNSBoard Committee Change
27th Jul 202011:21 amRNSAdditional Listing
24th Jul 20203:24 pmRNSAgreement with US Department of Justice
17th Jul 20202:31 pmRNSHolding(s) in Company
16th Jul 20201:00 pmRNSNotice of Results
8th Jul 20208:00 amRNSHolding(s) in Company
1st Jul 20207:00 amRNSStatement re US Gov’t Agreement with Former CEO
29th Jun 20207:00 amRNSAppointment of Chief Executive Officer
24th Jun 202012:35 pmRNS24-Month Outcomes of RECOVER Study Presented
18th Jun 202011:36 amRNSHolding(s) in Company
15th Jun 20204:12 pmRNSHolding(s) in Company
15th Jun 20207:00 amRNSStatement regarding Indivior Chair
3rd Jun 20207:00 amRNSIndivior Announces PTAB Ruling
22nd May 20208:00 amRNSHolding(s) in Company
20th May 20202:00 pmRNSIndivior to Participate in Conference
14th May 202012:00 pmRNS1st Quarter Results
14th May 20209:13 amRNSHolding(s) in Company
11th May 202010:44 amRNSBlock listing Interim Review
7th May 20205:23 pmRNSResult of AGM
1st May 20208:00 amRNSTotal Voting Rights
27th Apr 20207:00 amRNSDirectorate Change
23rd Apr 20204:37 pmRNSHolding(s) in Company
20th Apr 20207:00 amRNSNotice of Results
16th Apr 20201:00 pmRNSImportant update regarding AGM
16th Apr 20207:00 amRNSIndivior announces 12-month safety data published
8th Apr 20207:00 amRNSIndivior Provides Business Update
25th Mar 20203:47 pmRNSHolding(s) in Company
25th Mar 20203:20 pmRNSHolding(s) in Company
23rd Mar 20203:47 pmRNSHolding(s) in Company
23rd Mar 20209:00 amRNSOne-Year Outcomes of RECOVER Study Published
20th Mar 20201:09 pmRNSHolding(s) in Company
19th Mar 20202:35 pmRNSHolding(s) in Company
13th Mar 20202:00 pmRNSDirector/PDMR Shareholding
13th Mar 202012:00 pmRNSAnnual Financial Report
11th Mar 20203:57 pmRNSHolding(s) in Company
10th Mar 20202:30 pmRNSDirector/PDMR Shareholding
9th Mar 20209:11 amRNSHolding(s) in Company
3rd Mar 20202:31 pmRNSDirector/PDMR Shareholding
2nd Mar 20209:31 amRNSTotal Voting Rights
25th Feb 20202:04 pmRNSDirector/PDMR Shareholding
25th Feb 20209:26 amRNSDirector/PDMR Shareholding
14th Feb 20207:00 amRNSHolding(s) in Company
13th Feb 20203:10 pmRNSBoard Committee Changes
13th Feb 20207:00 amRNSFinal Results
3rd Feb 202010:53 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.